// App-Quantinova.ai

: A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).

Researchers

Presenter

  • Evan Y. Yu

Principal Investigators

  • David Laidley

  • Frederic Pouliot

  • Stephan Probst

  • Fred Saad

  • Robert Sabbagh

  • A. Oliver Sartor

Medical Centers

  • University of Washington, Seattle, WA

  • St Josephs Health Care, London, Canada

  • Cancer Research Center, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Quebec City, QC, Canada

  • Jewish General Hospital, Montreal, QC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Universite de Sherbrooke, Sherbrooke, QC, Canada

  • Tulane Cancer Center, New Orleans, LA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Nephrology

  • Oncology (ONC)

  • Urology

  • Musculoskeletal

Disease

  • Metastatic castration-resistant prostate cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • 18F-DCFPyL

  • I 131

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • NA

Study Id's

  • NCT03939689

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved